NAFLD Clinical Trial - The Effect Of NS-0200 Versus Placebo On Hepatic Fat

Status Completed

Clinical Trial Summary

The goal of this study is to determine if NS-0200 can reduce the amount of liver fat in patients diagnosed with non-alcoholic fatty liver disease (NAFLD). This study will compare two doses of NS-0200 to placebo in NAFLD patients.

Clinical Trial Description

This is a randomized, 16-week, placebo-controlled, double-blind study to evaluate the effect of two fixed-dose combinations of leucine, metformin and sildenafil, NS-0200 compared to placebo, on the reduction of liver fat in patients diagnosed with non-alcoholic fatty liver disease (NAFLD). Subjects meeting all the inclusion criteria and no exclusion criteria will be randomized to one of three study arms.

The primary objective of this study is to evaluate the change in hepatic fat content assessed by proton-density-fat-fraction (PDFF) employing magnetic resonance imaging (MRI) in subjects from : Screening/Visit 2 (Day-7/Week-1) to Study Termination/Visit 8 (Day 112/Week 16) receiving two fixed-dose combinations of leucine, metformin and sildenafil compared to placebo. Secondary objectives will also assess changes in serum alanine aminotransferase (ALT) activity, change in circulating cytokeratin 18, a surrogate marker of necro-inflammation, change in HbA1c, change in fasting glucose, insulin and insulin sensitivity, change in blood lipids such as cholesterol, LDL, HDL, triglycerides, and changes in in C-reactive protein. In addition this study will evaluate the safety and tolerability of NS-0200.

Patients will have two screening visits, the first to determine their eligibility based on lab tests and the second based on the percentage of hepatic fat assessed by MRI imaging. Once qualified, patients will be randomly assigned to either one of the treatment groups or the placebo control group and monitored for a total of 16 weeks. Patients will return to the clinic each month for lab tests, and routine examinations. At the conclusion of the treatment period patients will again undergo an MRI scan to examine the percentage of hepatic fat. ;

Study Design

Related Conditions & MeSH terms

Fatty Liver
Liver Diseases
NAFLD
Non-alcoholic Fatty Liver Disease

Clinical Trial Details

NCT number	NCT02546609
Study type	Interventional
Source	NuSirt Biopharma
Contact
Status	Completed
Phase	Phase 2
Start date	November 19, 2015
Completion date	January 31, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06101433` - The Effect of Soy Isoflavones on Non-alcoholic Fatty Liver Disease and the Level of FGF-21 and Fetuin A	N/A
Completed	`NCT03289897` - Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan	N/A
Active, not recruiting	`NCT05479721` - LITMUS Imaging Study
Completed	`NCT05527938` - Web-based Interventions on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Children	N/A
Recruiting	`NCT06308757` - Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis	N/A
Completed	`NCT02654977` - CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy	Phase 2
Completed	`NCT02927184` - Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease	Phase 2
Completed	`NCT06047847` - Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption	N/A
Active, not recruiting	`NCT03534908` - Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: the Correlation Analysis and Risk Prediction Model Study
Recruiting	`NCT06098417` - Biomarkers in the Diagnosis and Prognosis of NAFLD
Recruiting	`NCT04564391` - Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins	N/A
Not yet recruiting	`NCT05984745` - Effect of CoQ10 on the Outcome of MAFLD Patients	Phase 2
Not yet recruiting	`NCT05052515` - The Effects of Natural Extracts Supplementation on NASH Patients	N/A
Recruiting	`NCT02459496` - Diabetes Nutrition Algorithms in Patients With Overt Diabetes Mellitus	N/A
Completed	`NCT01936779` - Understanding the Role of Dietary Fatty Acids on Liver Fat Metabolism in Humans	N/A
Completed	`NCT05844137` - Improving Detection and Evidence-based Care of NAFLD in Latinx and Black Patients With Type 2 Diabetes	N/A
Recruiting	`NCT04664036` - Prevalence, Incidence and Characteristics of NAFLD/NASH in Type 1 Diabetes Mellitus
Recruiting	`NCT04976283` - Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver	Phase 4
Recruiting	`NCT03587298` - Use of Shear Wave Elastography to Assess Non-alcoholic Fatty Liver Disease (NAFLD)
Completed	`NCT02952170` - Impact of Weight Loss Surgery in Adolescents With NAFLD	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms